Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03703895 · ClinicalTrials.gov registry record · Phase 4
A Study for a Topical Medication Versus Placebo in Patients With Hand Dermatitis
A Phase 4 study, sponsored by The Center for Clinical and Cosmetic Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT03703895: Completed Phase 4 study, sponsored by The Center for Clinical and Cosmetic Research.
NCT03703895 is a Phase 4 study that has completed, run by The Center for Clinical and Cosmetic Research. The registered enrollment target is 20 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03703895, a Phase 4 study, has completed, sponsored by The Center for Clinical and Cosmetic Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a double-blind, pilot study with 20 subjects to determine the tolerability and efficacy of topical AFX 5931 in the treatment of mild to moderate hand dermatitis. Subjects are screened up to 30 days before the baseline visit. Subjects who meet the eligibility criteria may qualify for the study. Subjects will be randomized in a 3:1 ratio to receive either the active or vehicle medication. 15 subjects will receive the active, therapeutic product and 5 subjects will receive the inactive, vehicle product.
Primary Outcome
To measure the efficacy of topical AFX 5931 in the treatment of mild to moderate hand dermatitis in subjects 12 years of age or older assessed via the Investigator's Global Assessment The investigator will rate the subject's hand dermatitis on a visual 5-point scale as follows: 0: Clear: No signs of HE 1. Almost clear: Just perceptible scaling and/or erythema; 2. Mild disease: Mild scaling and/or mild erythema, and/or mild cracking 3. Moderate disease: Moderate scaling and/or erythema, and/or
Interventions
- DRUG Topical Placebo
- DRUG Topical AFX5931
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-09-18 |
| Est. Completion | 2019-04-04 |
| Phase | Phase 4 |
What the finished NCT03703895 record still lists
NCT03703895 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Topical Placebo is the first listed.
NCT03703895 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03703895 about?
NCT03703895 is a clinical study titled "A Study for a Topical Medication Versus Placebo in Patients With Hand Dermatitis". This is a double-blind, pilot study with 20 subjects to determine the tolerability and efficacy of topical AFX 5931 in the treatment of mild to moderate hand dermatitis. Subjects are screened up to 30 days before the baseline visit. Subjects who meet the eligibility criteria may qualify for the stud...
What is the current status of trial NCT03703895?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2018-09-18. Estimated completion is 2019-04-04.
What interventions are being tested in trial NCT03703895?
The interventions under investigation include: Topical Placebo (DRUG), Topical AFX5931 (DRUG).
Who is sponsoring clinical trial NCT03703895?
This trial is sponsored by The Center for Clinical and Cosmetic Research, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03703895's enrollment target sits among peer trials
20 1753rd of 2000 higher than 167 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI